Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Recurrent fusion of MYB a… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck

Artikel i vetenskaplig tidskrift
Författare Marta Persson
Ywonne Andrén
Joachim Mark
H. M. Horlings
Fredrik Persson
Göran Stenman
Publicerad i Proceedings of the National Academy of Sciences
Volym 106
Nummer/häfte 44
Sidor 18740-4
ISSN 1091-6490
Publiceringsår 2009
Publicerad vid Institutionen för biomedicin, avdelningen för patologi
Sidor 18740-4
Språk en
Länkar dx.doi.org/10.1073/pnas.0909114106
Ämnesord Adult, Aged, Base Sequence, Breast Neoplasms/*genetics/*pathology, Carcinoma, Adenoid Cystic/*genetics/*pathology, Chromosomes, Human, Pair 6/genetics, Chromosomes, Human, Pair 8/genetics, Female, Gene Expression Regulation, Neoplastic, Head and Neck Neoplasms/*genetics/*pathology, Humans, Leukemia-Lymphoma, Adult T-Cell/genetics, Male, MicroRNAs/genetics, Middle Aged, Molecular Sequence Data, Oncogene Proteins, Fusion/genetics/*metabolism, RNA, Messenger/genetics/metabolism, Translocation, Genetic
Ämneskategorier Cell- och molekylärbiologi

Sammanfattning

The transcription factor gene MYB was identified recently as an oncogene that is rearranged/duplicated in some human leukemias. Here we describe a new mechanism of activation of MYB in human cancer involving gene fusion. We show that the t(6;9)(q22-23;p23-24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB. The minimal common part of MYB deleted as the result of fusion was exon 15 including the 3'-UTR, which contains several highly conserved target sites for miR-15a/16 and miR-150 microRNAs. These microRNAs recently were shown to regulate MYB expression negatively. We suggest that deletion of these target sites may disrupt repression of MYB leading to overexpression of MYB-NFIB transcripts and protein and to activation of critical MYB targets, including genes associated with apoptosis, cell cycle control, cell growth/angiogenesis, and cell adhesion. Forced overexpression of miR-15a/16 and miR-150 in primary fusion-positive ACC cells did not significantly alter the expression of MYB as compared with leukemic cells with MYB activation/duplication. Our data indicate that the MYB-NFIB fusion is a hallmark of ACC and that deregulation of the expression of MYB and its target genes is a key oncogenic event in the pathogenesis of ACC. Our findings also suggest that the gain-of-function activity resulting from the MYB-NFIB fusion is a candidate therapeutic target.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?